Search the Newsreel

Discipline and Rules-Based Execution in KROS Response

This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) with AI-generated trading strategies. It identifies a near-term weak sentiment, suggesting a potential resumption of long-term weakness, and highlights an exceptional 103.7:1 risk-reward short setup. The piece provides specific entry, target, and stop-loss levels for position, …

Kross Sets Q1 Earnings Call For July 27 At 10 AM

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros Therapeutics (KROS) is entering 2026 with a focus on three key catalysts expected to reshape investor sentiment. These include the planned Q2 2026 phase II initiation of rinvatercept in Duchenne muscular dystrophy, regulatory discussions for rinvatercept in ALS in the second half of …

Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan

Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of KROS common stock on July 15, 2026, at a weighted-average price of $10.61 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in December 2025, increasing his direct holdings to …

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

Keros Therapeutics (KROS) significantly reshaped its financial profile in 2025 through a major licensing deal with Takeda for elritercept, leading to a surge in revenue and a reduction in R&D expenses. While this extended Keros' cash runway into the first half of 2028 and …

BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics

BlackRock Portfolio Management LLC has disclosed a 5.7% beneficial ownership in Keros Therapeutics, Inc., holding 1,122,874 shares of common stock. This information was reported via a Schedule 13G SEC filing, indicating BlackRock's passive investment intentions. The firm maintains sole voting power over 991,089 shares …

Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher

Insiders at Keros Therapeutics sold shares at an average price of US$15.15 over the past year, before the stock price dropped 12% in the last week. Despite the recent dip, the current share price of US$10.61 is still below the average selling price, suggesting …

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages

Keros Therapeutics (NASDAQ:KROS) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $20.40. Recent analyst downgrades and a significant miss on latest quarterly earnings, with a loss of $1.21 per share and revenue of $0.37 million, have …

Kross Ltd (NSE:KROSS) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Supply ...

Kross Limited Re-Appoints GWC Professional Services as Internal Auditor for FY27

Kross Limited Commissions India's First Seamless Axle Beam Plant with 60% Capacity Boost

The recent 10% gain must have brightened CEO Sudhir Rai's week, Kross Limited's (NSE:KROSS) most bullish insider

Kross Limited's (NSE:KROSS) Stock Is Going Strong: Have Financials A Role To Play?

Kross Limited Reports 6% Revenue Decline in Q2 FY26 Amid Commercial Vehicle Slowdown